AlphaStocks

ABBV vs FTI

AbbVie Inc. vs TechnipFMC plc — Side-by-Side Stock Comparison

ABBV

AbbVie Inc.

5.7

Consider Buy

$208.23

FTI

TechnipFMC plc

8.4

Strong Buy

$74.59

ABBV vs FTI: Which is the Better Investment?

AbbVie Inc. (ABBV) scores 5.7/10 while TechnipFMC plc (FTI) scores 8.4/10 on AlphaStocks' composite model. TechnipFMC plc has the higher composite rating of Strong Buy. On a P/E basis, TechnipFMC plc trades at 32.5x, making it the more attractively priced of the two.

This comparison is algorithmically generated and is not financial advice.

MetricABBVFTI
Scores & Fundamentals
Composite Score5.7/108.4/10
RatingConsider BuyStrong Buy
Price$208.23$74.59
P/E Ratio87.432.5
ROE-143.0%28.8%
Market Cap$369B$31B
Fair Value$110.29$49.72
Dividend Yield3.2%
Sector Rank#328 of 1126#2 of 1126
Model Verdicts
PiotroskiStrongStrong
BuffettStrongStrong
GrahamNeutralCaution
LynchNeutralStrong
GreenblattNeutralNeutral
View full ABBVanalysis →View full FTIanalysis →
Compare any two stocks →

ABBV vs FTI: Which Stock Scores Higher?

AbbVie Inc. (ABBV) and TechnipFMC plc (FTI) are among the most compared stocks in the S&P 500. FTI currently leads with a composite score of 8.4/10 (Strong Buy) compared to ABBV's 5.7/10 (Consider Buy).

The AlphaStocks composite score evaluates each stock across four dimensions: Quality (business strength measured by Piotroski F-Score and Buffett quality criteria), Value (discount to intrinsic worth using Graham, Lynch, and Greenblatt models), Momentum (6-month price trend), and Timing (a confirmation signal that requires both value and momentum to align). A higher composite score indicates stronger overall fundamentals combined with favorable market conditions.

This comparison uses the same scoring framework for both companies, ensuring an apples-to-apples evaluation. Scores are recalculated daily after market close using data from SEC filings and market prices. Read the full methodology to understand how each model contributes to the composite score.

Scores are algorithm-generated research tools, not investment recommendations. Past performance does not guarantee future results. Always do your own due diligence. Full disclaimer